Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
 |
 |
 |
|
||
 |
|
 |
|
||
investor relations
Napo believes that the focus on global populations with its proprietary pharmaceutical products will enhance the return to its investors while simultaneously addressing global health needs.
Global markets represent 8 to 10 times the population of the western marketplace typically targeted by the pharmaceutical industry. Larger volume of product typically translates to lower cost of goods sold, which increases profitability in western territories, where Napo benefits from profit sharing relationships; and increases market access in emerging and developing economies, where Napo benefits from royalties on top line sales.
Napo intends to execute analogous global development and commercialization strategies with all its products.
The company has a commitment to investor relations and education regarding
its strategy and how sustainable and responsible business practices benefit
the company's reputation, employee retention, global visibility, and return
on investment opportunity.